Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Symptomatic haemorrhoids, or piles, have significant effects on quality of life. The treatment for advanced disease is surgical excision (haemorrhoidectomy) which is extremely effective. However, pain following haemorrhoidectomy is known by all to be a miserable experience and current treatment is not very effective. We have formulated a new cream treatment which targets three theorised mechanisms of pain after haemorrhoidectomy. We will test the effectiveness of the treatments with a multi-centred randomised controlled factorial trial with four parallel double-blinded arms containing different combinations of the active agents. The outcomes include pain scores, amount of analgesia required and time to return to work. The results of our study could provide evidence of an effective treatment for post haemorrhoidectomy pain. The treatment may provide considerable benefit to patients undergoing this surgical procedure.
Study Design: This will be a patient-and-investigator blinded factorial randomised trial with four parallel groups. Participants in all four groups will be instructed to apply cream 3 times a day for 7 days after surgery. A standard analgesia prescription will be provided with laxatives as per routine care. Patients will be provided a questionnaire to complete and return on day 14.
Random Sequence Generation: Computer generated sequence allocating patients to a 1:1:1:1 ratio using permuted block randomisation in blocks of 12.
Allocation Concealment: This randomisation code will be seeded to the pharmacist to who will package and label the cream according to a code. The creams will be indistinguishable to which active ingredient they contain.
Assignment of intervention: Patients will be assigned in order according to the numbering of the cream tubes by the blinded investigator.
Data recording: Data will be recorded on Redcap database.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Metronidazole | Active Comparator | Group A receiving 10% metronidazole cream |
|
| Metronidazole + Diltiazem | Active Comparator | Metronidazole 10% + Diltiazem 2% |
|
| Metronidazole + Lignocaine | Active Comparator | Metronidazole 10% + Lignocaine 4% |
|
| Metronidazole + Diltiazem + Lignocaine | Active Comparator | Metronidazole 10% + Diltiazem 2% + Lignocaine 4% |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Metronidazole cream | Drug | 10% metronidazole applied rectally |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Pain scores | Measured by visual analog scale, 1-10cm, continuous, the higher the score, the worse the pain | 7 days |
| Amount of analgesic use | Morphine equivalent amount | 7 days |
| Measure | Description | Time Frame |
|---|---|---|
| Return to work | Day post-operation when the patient returns to work | 14 days |
| Pain on bowel motion: Visual Analog Scale | Measured by Visual Analog Scale, continuous 1-10cm, the higher the score, the worse the pain. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Andrew G Hill, MBChB, MD, EdD, FRACS, FACS | Counties Manukau Health | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Counties Manukau District Health Board | Auckland | 1041 | New Zealand |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 38871679 | Derived | Jin JZ, Xia W, Gao R, Vandal AC, Weston M, Israel L, Connolly A, Singh PP, Svirskis D, Hill A. A Randomized Controlled Trial of Topical Analgesia Posthemorrhoidectomy (TAPH Trial). Dis Colon Rectum. 2024 Sep 1;67(9):1158-1168. doi: 10.1097/DCR.0000000000003419. Epub 2024 Jun 11. |
Not provided
Not provided
Will be shared when results become available.
When results are available for 12 months
email request
Not provided
Not provided
| ID | Term |
|---|---|
| D006484 | Hemorrhoids |
| ID | Term |
|---|---|
| D012002 | Rectal Diseases |
| D007410 | Intestinal Diseases |
| D005767 | Gastrointestinal Diseases |
| D004066 | Digestive System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D008795 | Metronidazole |
| D004110 | Diltiazem |
| ID | Term |
|---|---|
| D009593 | Nitroimidazoles |
| D009574 | Nitro Compounds |
| D009930 | Organic Chemicals |
| D007093 | Imidazoles |
Not provided
Not provided
Parallel with 1:1:1:1 Allocation.
Not provided
Not provided
Double blinded trial, both participant and investigator are blinded.
| Metronidazole and Diltiazem cream |
| Drug |
Combination Metronidazole and Diltiazem applied rectally |
|
| Metronidazole and Lidocaine cream | Drug | Combination metronidazole and lignocaine applied rectally |
|
| Metronidazole, Diltiazem and Lidocaine cream | Drug | Combination of all active agents tested applied rectally |
|
| 7 days |
| Complications | Rates of Bleeding | 30 days |
| Re-admission | Rates of Re-admission to hospital, | 30 days |
| Repeat Prescription | Rates of Repeat Prescription Requirement | 30 days |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D001393 |
| Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D001552 | Benzazepines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |